O-011 Low-dose IL-2 Administration Expands Human Regulatory T Cells in Patients with UC and Humanized Mice and Protects Against Experimental Colitis

    loading  Checking for direct PDF access through Ovid



Treg dysfunction or deficiency results in unopposed immune activation and autoimmunity. Interleukin-2 (IL-2) is critical for the expansion, suppressive function, and maintenance of Tregs. Although conventional T cells and NK cells respond to IL-2, Tregs are more sensitive to lower concentrations of IL-2 due to constitutive expression of CD25, the high affinity IL-2 receptor. Low-dose IL-2 therapies have shown to preferentially expand Tregs and ameliorate manifestations of graft versus host disease (Koreth et al., NEJM 2011) and HCV-associated vasculitis (Saadoun et al., NEJM 2011). Thus, low-dose IL-2 is an attractive therapeutic approach to expand Tregs in vivo for treating ulcerative colitis (UC). We utilized humanized mice to test the ability of low-dose IL-2 to expand human Tregs in vivo and ameliorate experimental colitis. Moreover, we initiated a clinical trial to evaluate whether low-dose IL-2 therapy in patients with UC could expand Tregs and ameliorate disease.


To demonstrate sensitivity of human Tregs to IL-2, peripheral blood mononuclear cells (PBMCs) from UC patients were stimulated in vitro with low-dose IL-2 (10 IU/mL) and STAT5 phosphorylation was assessed by flow cytometry. For humanized mouse studies, 8-week old female NOD.Prkdcscid.Il2rg−/− (NSG) mice were administered daily intraperitoneal injections of IL-2 (Proleukin; 10k or 50k units) or PBS as a control. Two days following IL-2 injections, mice were reconstituted with 2 × 107 PBMCs isolated from healthy donors. To induce colitis, mice were administered a single DNBS enema on day 7 and weighed daily. Mice were euthanized on day 10 and immunophenotyping was performed on blood, spleen, and colonic lamina propria by flow cytometry while colon histology was scored on H&E stained sections. To evaluate the effect of low-dose IL-2 in patients with UC, 1 patient was enrolled under clinical trial #NCT02200445 and was administered daily subcutaneous injections of IL-2 (1.0 × 106 IU/m2). Tregs in peripheral blood were assessed at baseline and weekly thereafter by flow cytometry.


In vitro stimulation of PBMCs from UC patients with low-dose IL-2 induced STAT5 phosphorylation in Tregs but not Tcons. DNBS-treated humanized mice that were administered 10k or 50k IL-2 exhibited a greater percentage of CD4+CD25+CD127lo/− Tregs compared to PBS-treated controls in blood (32% and 41% versus 22%), spleen (16% and 31% versus 11%), and colon (6% and 10% versus 5%). Evaluation of colons from DNBS-treated humanized mice showed preservation of colon length in mice receiving 10k or 50k IL-2 corresponding to reduction in colitis histology scores (0.5 and 1.5 versus 2.75). The patient with UC enrolled in the low-dose IL-2 clinical trial had a baseline measurement of 2.1% CD4+CD25+CD127lo/− Tregs in the peripheral blood that increased to 36.2% after 7 days and 23.7% after 14 days of low-dose IL-2 treatment.


Our data demonstrate that humanized mice are a valuable translational research tool that validated the effects of low-dose IL-2 in expanding human Tregs in vivo and will be a useful platform in which to assess human therapeutics or drug targets prior to clinical applications. Finally, preliminary data in UC patients demonstrate that Tregs are selectively expanded by low-dose IL-2 in vitro and in vivo.

Related Topics

    loading  Loading Related Articles